Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...
A new study sought to identify the frequency and determinants of flares for with people with systemic lupus erythematosus (SLE) with persistently active disease (PAD). Researchers found that both ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...
Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...
In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...
Johns Hopkins surgeon and writer Dr Martin Makary, President Donald Trump's pick to lead the FDA, faced a grilling today by ...
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) is anticipated to release its earnings data before the market opens on ...
23h
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback